M&A / Deals Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb PharmaTimesPartnership to develop nextgeneration Tcell engagers for solid tumoursM&A / DealsRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) PharmaTimes Partnership to develop nextgeneration Tcell engagers for solid tumours M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Innovent’s CDMO gets green light to make biologics at large Chinese plantNext: Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinic Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
